消斑汤治疗高危非致残性缺血性脑血管病的临床观察

Clinical effect of Xiaoban Decoction on HR-NICE

目的:观察消斑汤治疗高危非致残性缺血性脑血管病(HR-NICE)的临床效果。方法:选取80例HR-NICE痰热证患者作为研究对象,分为观察组(40例)与对照组(40例),对照组采用常规降血脂、抗血小板等治疗;观察组在对照组基础上加用消斑汤口服,两组均治疗3个月。比较两组治疗期间的复发情况,治疗前后的血清同型半胱氨酸(Hcy)、超敏C反应蛋白(hs-CRP)及血脂的变化。结果:观察组3个月内复发率低于对照组,差异有统计学意义(P<0.05);观察组的Hcy、Hs-CRP、低密度脂蛋白、三酰甘油、总胆固醇水平在治疗后均低于治疗前,差异有统计学意义(P<0.05)。组间比较发现:观察组治疗后的hs-CRP、低密度脂蛋白、总胆固醇水平均低于对照组,差异有统计学意义(P<0.05)。结论:消斑汤可以降低HR-NICE痰热证患者卒中复发率,降低患者血清Hcy、hs-CRP、血脂水平。

Objective To investigate the clinical effect of Xiaoban Decoction in the treatment of high-risk non-disabling ischemic cerebrovascular disease(HR-NICE).Methods 80 patients with HR-NICE phlegm-heat syndrome were selected as the research objects,and they were divided into observation group(40 cases)and control group(40 cases).The control group was treated with conventional hypolipidemic and antiplatelet treatments.The observation group was based on the control group.Xiaoban Decoction was added orally,and both groups were treated for 3 months.The recurrence of the two groups of patients during the treatment period,the changes of serum homocysteine(Hcy),high-sensitivity C-reactive protein(hs-CRP)and blood lipids before and after treatment were compared.Results The recurrence rate of patients in the observation group was lower than that in the control group within 3 months,and the difference was statistically significant(P<0.05);the levels of Hcy,Hs-CRP,low-density lipoprotein,triacylglycerol,and total cholesterol in the observation group were under treatment After all were lower than before treatment,the difference was statistically significant(P<0.05).The comparison between groups found that the Hs-CRP,low-density lipoprotein,and total cholesterol levels of the observation group after treatment were lower than those of the control group,and the difference was statistically significant(P<0.05).Conclusion Xiaoban Decoction can reduce the recurrence rate of stroke in patients with HR-NICE phlegm-heat syndrome.Xiaoban Decoction can reduce serum Hcy,hs-CRP and blood lipid levels in patients with HR-NICE phlegm-heat syndrome.